Lantern Pharma Inc.’s Q4 2024 Earnings Call: Key Insights
On March 27, 2025, at 4:30 AM ET, Lantern Pharma Inc. (NASDAQ: LTRN) held its Fourth Quarter and Year End 2024 Earnings Call. The participants from Lantern Pharma were Panna Sharma, President and CEO; David Margrave, Chief Financial Officer; and Kishor Bhatia, Chief Scientific Officer. The call was operated by an unnamed conference call operator.
Company Participants’ Remarks
Panna Sharma: During the call, Panna Sharma began by addressing the company’s financial performance in Q4 2024. He reported that Lantern Pharma had achieved record revenues and a significant increase in net income compared to the same period the previous year. Sharma also discussed the company’s progress in bringing new drugs to market and the potential for future growth.
David Margrave: David Margrave provided a detailed analysis of Lantern Pharma’s financial statements for Q4 2024. He highlighted the company’s strong cash position and its ability to fund ongoing operations and research and development initiatives.
Kishor Bhatia: Kishor Bhatia discussed the scientific progress made by Lantern Pharma in the development of its pipeline of drugs. He provided updates on ongoing clinical trials and the potential for new indications for existing drugs.
Impact on Individuals
The earnings call provided important information for investors in Lantern Pharma, as it offered insights into the company’s financial performance and future prospects. The strong financial results reported by Sharma and Margrave, coupled with Bhatia’s updates on the company’s drug development pipeline, may have led to increased confidence in the stock and a potential price increase.
Impact on the World
Beyond its impact on investors, Lantern Pharma’s progress in drug development has the potential to benefit patients around the world. The company’s pipeline includes drugs for various indications, including cancer, neurological disorders, and infectious diseases. Successful development and approval of these drugs could lead to new treatment options for patients and potentially improve their quality of life.
Conclusion
Lantern Pharma’s Q4 2024 Earnings Call provided investors with valuable insights into the company’s financial performance and future prospects. Additionally, the call offered updates on the company’s drug development pipeline, which has the potential to benefit patients around the world. The strong financial results reported by Lantern Pharma may lead to increased confidence in the stock and potential price growth. Overall, the call was a positive indicator for both investors and those who stand to benefit from the company’s drug development initiatives.
- Lantern Pharma reported record revenues and a significant increase in net income in Q4 2024
- The company’s drug development pipeline includes potential treatments for various indications
- Strong financial results may lead to increased confidence in the stock and potential price growth
- Successful development and approval of Lantern Pharma’s drugs could lead to new treatment options for patients
